A proof-of-concept study of BLU-808 for the treatment of mast cell activation syndrome
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs BLU 808 (Primary)
- Indications Mastocytosis
- Focus Adverse reactions; Proof of concept
- 17 Jan 2025 New trial record
- 12 Jan 2025 According to a Blueprint Medicines media release, company to initiate this trial second half of 2025.